A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients. (PRIORITI)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to assess the benefit of immediate hormonal treatment after Radical Prostatectomy in Chinese and Russian patients with high risk prostate cancer. To reach this target, the trial will compare a group of patients treated with triptorelin at 8 weeks after the surgery and for a duration of 9 months (3 injections) versus another group (called "active surveillance group") who will be not receiving triptorelin. Both groups will be followed every 3 months to monitor any sign of disease progression during a minimum of 36 months
Full description
This trial is a phase IV (in Russia and China) as approved indication is locally advanced or metastatic prostate cancer in both countries.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Histopathologically confirmed adenocarcinoma of the prostate
- Radical Prostatectomy with curative intent performed no more than 8 weeks before randomisation
- High risk criteria of disease progression, defined as follows:
Gleason score ≥8 on prostatectomy specimen, and/or Pre RP PSA level ≥20 ng/mL, and/or Primary tumour stage 3a (pT3a) (with any PSA level and any Gleason score)
- Post-RP PSA levels ≤0.2 ng/mL at 6 weeks
Exclusion criteria
- Evidence of lymph nodes or distant metastasis
- Positive margins
- Evidence of any other malignant disease, not treated with a curative intent
- Had surgical castration
Trial design
Primary purpose
Allocation
Interventional model
Masking
226 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal